- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04414488
The Impact of Regional Anaesthesia on Hormone Levels in Thoracic Surgery.
May 30, 2020 updated by: Piotr Palaczyński, Medical University of Silesia
Basic aspects of thoracic anaesthesia are general anesthesia often combined with regional anesthesia, intubation with double lumen tube and separation of lung ventilation.
Proper assessment of pain and adequate analgesia in intraoperative and postoperative period is a challenging issue for medical practitioners.
Intraoperative trauma may lead to many metabolic implications and disturbance of haemostasis, what can be reflected in change of blood and saliva hormone and other substance levels.
The aim of this study is to assess the impact of regional anesthesia on hormone levels in patients requiring videothoracoscopic procedures.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Basic aspects of thoracic anaesthesia are general anesthesia often combined with regional anesthesia, intubation with double lumen tube and separation of lung ventilation.
Proper assessment of pain and adequate analgesia in intraoperative and postoperative period is a challenging issue for medical practitioners.
Intraoperative trauma may lead to many metabolic implications and disturbance of haemostasis, what can be reflected in change of blood and saliva hormone and other substance levels, such as alpha-amylase, cortisol, testosterone, secretory IgA, β-endorphin, nerve growth factor, calcitonin gene-related protein and P substance.
The aim of this study is to assess the impact of regional anesthesia on hormone levels in postoperative period.
Saliva was collected from participants in order to perform laboratory tests, using a special disposable Salivette tube (Sarstedt AG & Co, Germany).
Saliva was collected by placing a sterile tampon under the tongue or chewing for 30-45 seconds.
The soaked saliva pad was then placed in a suspended insert with a perforated bottom.
The insert with a tampon was placed in a centrifuge tube and closed with a stopper.
Next the tube was centrifuged (1000 x g for 10 min.) to obtain a ready to test saliva supernatant.
Approximately 0,7 ml of the supernatant from every sample collected was used for further testing.
Samples were frozen after centrifugation at - 85°C until performing laboratory tests.
Blood was collected for laboratory tests from the ulnar vein.
Blood for testing was collected using disposable equipment in a volume of 5ml into a tube containing ethylenediaminetetraacetic acid (EDTA) and aprotinin.
Next the tube was centrifuged (1000 x g for 5 min.).
After centrifugation and separation of morphotic elements, the obtained plasma was divided into two tubes and frozen at - 85°C until performing laboratory tests.
Study Type
Observational
Enrollment (Actual)
119
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Silesia
-
Zabrze, Silesia, Poland, 41-800
- Samodzielny Publiczny Szpital Kliniczny nr 1
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Study population consisted of consecutive patients scheduled for elective videothoracoscopic procedures.
Description
Inclusion Criteria:
-qualification to elective videothoracoscopic procedures and general anaesthesia
Exclusion Criteria:
- lack of consent to participation in the study,
- significant coagulopathy,
- contraindication to the thoracic paravertebral block or drugs used in protocol,
- history of chronic pain,
- chest wall neoplastic invasion,
- previous thoracic spine surgery,
- mental state preventing from effective use of PCA device,
- renal failure (GFR <60 ml/min/1,73 m2).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patient controlled analgesia
General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1.
Anaesthesia was maintained with one minimal alveolar concentration sevoflurane.
Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced.
After surgery, if a patient complained of pain then she/he was given i.v.
oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA).
The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min.
During the night, basal rate oxycodone was 2-4 mg per hour.
Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
|
|
|
Thoracic paravertebral block and patient controlled analgesia
Before induction of general anesthesia thoracic paravertebral block was performed.
General anaesthesia was induced with midazolam 0.1 mg*kg-1, propofol 2 mg*kg-1, cisatracurium 0.15 mg*kg-1 and fentanyl 1.5 µg*kg-1.
Anaesthesia was maintained with one minimal alveolar concentration sevoflurane.
Fractional doses of fentanyl 1-3 µg*kg-1 were administered if heart rate or mean blood pressure rose more than 20% above the base-line value obtained just before surgery commenced.
After surgery, if a patient complained of pain then she/he was given i.v.
oxycodone by an anaesthetist before commencing the patient controlled analgesia (PCA).
The PCA solution was oxycodone (1mg*ml-1) and the PCA was programmed to allow a self-administered bolus dose of 1mg oxycodone with a lockout time of 5 min.
During the night, basal rate oxycodone was 2-4 mg per hour.
Additionally, patients were given 1g intravenous paracetamol every 6h and 100mg of intravenous ketoprofen every 12h, if required.
|
Before the induction of general anaesthesia a single-shot ThPVB was performed at the Th3 to Th4 level, approximately, 2.5 to 3 cm lateral to tip of a spinous process.
A preblock ultrasound examination was undertaken to assess the depth of the transverse process and the pleura.
An insulated 10 cm long needle was used and this was connected to a peripheral nerve stimulator with a set current of 2.5 milliampere(mA).
The current was gradually reduced as the needle was inserted until the appearance of visible intercostal muscles activity with a current of 0.3 to 0.5mA (paravertebral space identification).
Plain bupivacaine (0.3 ml*kg-1) was then injected after a negative aspiration test for air or blood.
The efficacy of the blockade to cold was checked after 20 min with a plastic ampoule of saline kept in the freezer.
Testing was symmetrical on both sides of thorax.
A difference in sensation to cold between the blocked and unblocked sides was taken to indicate an effective block.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Alpha-amylase activity. [U/ml]
Time Frame: 24 hours
|
α-amylase activity assay was performed by a static method with AMYLAZA kit (Aqua-Med Łodz, Poland).
The samples were diluted 100 times using 0,9% chloride solution.
2-chloro-4-nitrofenylo-maltotrioside is a substrate in this method.
The reaction was performed in pH 6,0 MES buffer at 37 ° C rendering a colored reaction product.
The product was then analyzed via spectrophotometry at 405 nm.
Results are presented in salivary α-amylase activity units (U/ml).
Measurement imprecision of the method was 4.1%.
Material was collected after enrollment to the study (T0), six hours after the surgery (T1) and 24 hours after the surgery (T2).
|
24 hours
|
|
Cortisol concentration. [ng/ml]
Time Frame: 24 hours
|
The commercial ELISA (Diapra, Italy) was used to determine the concentration of cortisol.
The analytical procedure was in accordance with the manufacturer's instructions in the technical manuals supplied with the kits.
Absorbance readings were taken using a µQuant reader (Biotek, USA), while results were processed using KCJunior (Biotek, USA).
The sensitivity of the method was 0,12 ng/ml for cortisol.
The method's imprecision was 6.2%.
Material was collected after enrollment to the study (T0), six hours after the surgery (T1) and 24 hours after the surgery (T2).
|
24 hours
|
|
Testosterone concentration. [pg/ml]
Time Frame: 24 hours
|
The commercial ELISA (Diapra, Italy) was used to determine the concentration of testosterone.
The analytical procedure was in accordance with the manufacturer's instructions in the technical manuals supplied with the kits.
Absorbance readings were taken using a µQuant reader (Biotek, USA), while results were processed using KCJunior (Biotek, USA).
The sensitivity of the method was 3,28 pg/ml for testosterone.
The method's imprecision was 7.9%.
Material was collected after enrollment to the study (T0), six hours after the surgery (T1) and 24 hours after the surgery (T2).
|
24 hours
|
|
Secretory Immunoglobulin A concentration. (sIgA)
Time Frame: 24 hours
|
The commercial ELISA (Immunodiagnostic AG, Niemcy.) were used to determine the concentration of sIgA.
The analytical procedure was in accordance with the manufacturer's instructions in the technical manuals supplied with the kits.
Absorbance readings were taken using a µQuant reader (Biotek, USA), while results were processed using KCJunior (Biotek, USA).
Material was collected after enrollment to the study (T0), six hours after the surgery (T1) and 24 hours after the surgery (T2).
|
24 hours
|
|
β-endorphin concentration.
Time Frame: 24 hours
|
Determination of β-endorphin concentration was preceded by extraction on C18 Sep-Pak columns containing 50mg C18, using trifluoroacetic acid (TFA) and elution buffer (i.e.
60% acetonitrile, 1% TFA and 39% distilled water).
The extracts obtained were lyophilized.
To determine the concentration of β-endorphins in the tested samples, lyophilisates were dissolved in an appropriate amount of buffer, and then commercial ELISA tests from Elabscience, USA were used.
The analytical procedure was in accordance with the manufacturer's instructions in the technical manuals supplied with the kits.
Absorbance readings were taken using a µQuant reader (Biotek, USA), while results were processed using KCJunior (Biotek, USA).
Material was collected after enrollment to the study (T0), six hours after the surgery (T1) and 24 hours after the surgery (T2).
|
24 hours
|
|
P substance concentration. [pg/ml]
Time Frame: 24 hours
|
The commercial ELISA test was used to determine the concentration of P substance.
The analytical procedure was in accordance with the manufacturer's instructions in the technical manuals supplied with the kits.
Material was collected after enrollment to the study (T0), six hours after the surgery (T1) and 24 hours after the surgery (T2).
|
24 hours
|
|
Nerve Growth Factor concentration. [ng/ml]
Time Frame: 24 hours
|
The commercial ELISA test was used to determine the concentration of the Nerve Growth Factor.
The analytical procedure was in accordance with the manufacturer's instructions in the technical manuals supplied with the kits.
Material was collected after enrollment to the study (T0), six hours after the surgery (T1) and 24 hours after the surgery (T2).
|
24 hours
|
|
Calcitonin Gene-related Peptide concentration. [pg/ml]
Time Frame: 24 hours
|
The commercial ELISA test was used to determine the concentration of the Calcitonin Gene-related Peptide.
The analytical procedure was in accordance with the manufacturer's instructions in the technical manuals supplied with the kits.
Material was collected after enrollment to the study (T0), six hours after the surgery (T1) and 24 hours after the surgery (T2).
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain intensity (NRS)
Time Frame: 24 hours
|
Pain intensity at rest was recorded with Numerical Rating Scale (NRS) at 0, 6, 12, 18 and 24 postoperative hours.
Patient determined intensity of symptoms on a 10 grade scale, where 0 corresponded to no pain and 10 corresponded to the strongest possible pain.
|
24 hours
|
|
Arterial blood pressure [mmHg]
Time Frame: 24 hours
|
Non-invasive arterial blood pressure was recorded at 0, 6, 12, 18 and 24 postoperative hours.
|
24 hours
|
|
Heart rate [bmp]
Time Frame: 24 hours
|
Heart rate was recorded in continuous manner up to 24 postoperative hours.
|
24 hours
|
|
Arterial blood saturation measured by pulse oximetry [%]
Time Frame: 24 hours
|
Arterial blood saturation was recorded in continuous manner up to 24 postoperative hours.
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2018
Primary Completion (Actual)
December 1, 2019
Study Completion (Actual)
December 1, 2019
Study Registration Dates
First Submitted
May 30, 2020
First Submitted That Met QC Criteria
May 30, 2020
First Posted (Actual)
June 4, 2020
Study Record Updates
Last Update Posted (Actual)
June 4, 2020
Last Update Submitted That Met QC Criteria
May 30, 2020
Last Verified
May 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HL-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hormones
-
Qilu Hospital of Shandong UniversityNot yet recruiting
-
National Institute of Environmental Health Sciences...Completed
-
University of GlasgowRecruitingGastrointestinal HormonesUnited Kingdom
-
Umeå UniversityNot yet recruitingCytokines | HormonesSweden
-
University Medicine GreifswaldCompletedGastrointestinal HormonesGermany
-
Medipol UniversityNot yet recruitingVirtual Reality | Music | Hormones | BirthTurkey (Türkiye)
-
German Institute of Human NutritionRecruitingStress | Behavior | Cognition | Food Intake | HormonesGermany
-
Northern Care Alliance NHS Foundation TrustUniversity of ManchesterUnknownBlood Glucose | Hormones | Therapeutic Uses | AppetiteUnited Kingdom
-
University GhentCompleted
-
University of BirminghamCompletedNeural Responses | Appetite Hormones | Subjective Appetite SensationsUnited Kingdom
Clinical Trials on Thoracic paravertebral block (ThPVB)
-
Larissa University HospitalUnknownBreast Surgery | Autonomic Nervous System | Thoracic Paravertebral Block | HRVGreece
-
Tongji HospitalRecruitingPneumothorax | Acute Respiratory Distress Syndrome (ARDS) | Atelectasis | Video-assisted Thoracoscopic Surgery (VATS) | Bronchospasm | Lung Cancer (Diagnosis) | Pulmonary Infections | Bronchopleural Fistula | Pleural Effusion Due to Another Disorder (Disorder) | Pulmonary Embolism (Diagnosis) | Respiratory...China
-
Bursa City HospitalRecruitingPost-thoracotomy PainTurkey (Türkiye)
-
Tanta UniversityCompletedAnalgesia | Erector Spinae Plane Block | Paravertebral Block | Video-Assisted Thoracic Surgery | Transversus Thoracic Muscle Plane BlockEgypt
-
National Cancer Institute, EgyptRecruitingLung Cancer | Thoracotomy | Thoracic Paravertebral Block | Costotransverse Foramen BlockEgypt
-
Tanta UniversityCompleted
-
Zagazig UniversityRecruitingDiscitis of Thoracic RegionEgypt
-
Ciusss de L'Est de l'Île de MontréalRecruitingBreast Cancer | Breast Neoplasms | Breast Neoplasm Female | Cancer, BreastCanada
-
Tanta UniversityCompletedPost Thoracotomy Pain | Thoracic Paravertebral Block | External Oblique Intercostal Plane BlockEgypt